Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo

TBI-166, derived from riminophenazine analogues, is under development in a phase I clinical trial in China. TBI-166 showed more potent anti-tuberculosis (anti-TB) activity than did clofazimine in in vitro and animal experiments. To identify potent regimens containing TBI-166 in TB chemotherapy, TBI-...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Zhang, Ye, Zhu, Hui, Fu, Lei, Wang, Bin, Guo, Shaochen, Chen, Xi, Liu, Zhongquan, Huang, Haihong, Yang, Tianjian, Lu, Yu
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2019
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591646/
https://ncbi.nlm.nih.gov/pubmed/31061157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02496-18
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires